Loading...
01/10 03:22
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary highlights a 22% YoY revenue increase, improved operational efficiency, and strong growth in the dental division. The Q&A section reveals a new partnership with Axial Biologics, which is a positive catalyst. Despite some risks and uncertainties, the company's strong balance sheet and commitment to shareholder value are favorable. Overall, the positive financial performance, strategic partnerships, and operational improvements suggest a positive stock price movement over the next two weeks.
Revenue (Q3 2024) $2.5 million, a 22% increase from $2.1 million in Q3 2023, driven by strong growth in the dental division and resolution of logistic challenges.
International Revenue (Q3 2024) $1.3 million, an increase of $0.5 million compared to Q3 2023, due to resolving freight forwarder delays.
Gross Profit (Q3 2024) $1.8 million, or 73% of revenue, compared to $1.5 million and 73% of revenue in Q3 2023, due to higher international sales.
Operating Loss (Q3 2024) Approximately $1.5 million, a decrease of approximately $38,000 from Q3 2023.
Net Loss (Q3 2024) Approximately $1.5 million, or $0.02 per share, consistent with Q3 2023.
Revenue (9 months 2024) $6.6 million, a decrease from $7.6 million in the same period of 2023, due to international sales issues.
US E-commerce and Dental Service Revenue (9 months 2024) $3.9 million, an increase from $3.5 million in the same period of 2023.
International Revenue (9 months 2024) $2.7 million, a decrease of $0.6 million compared to the same period in 2023, due to freight forwarder issues.
Gross Profit (9 months 2024) $4.9 million, or 74% of revenue, compared to $5.3 million, or 70% of revenue in the same period of 2023.
Operating Loss (9 months 2024) Approximately $4.7 million, compared to approximately $5.1 million in the same period of 2023.
Net Loss (9 months 2024) $2.7 million, or $0.03 per share, compared to a net loss of $5 million and $0.07 per share for the same period in 2023, driven by the receipt of approximately $2 million from the sale of New Jersey net operating losses.
Cash and Cash Equivalents (as of September 30, 2024) Approximately $4.8 million, with working capital of $6.9 million and no long-term debt.
CompuFlo Epidural System: Substantial progress in rolling out the CompuFlo Epidural System, which offers real-time pressure feedback for precise needle placement. Achieved Medicare Part B physician payment rate assignment, enhancing adoption among pain management providers.
International Dental Sales: International dental sales increased by 57% due to resolved logistic challenges, contributing to a total revenue of $2.5 million for the quarter.
Brazil Market Entry: Secured regulatory approval to market CompuFlo in Brazil, targeting a significant opportunity with over 2.8 million births annually.
E-commerce Sales Model: Shift to an e-commerce sales model has improved customer engagement and gross margins, with a reported 11.4% growth in e-commerce business over nine months.
Partnership with Axial Biologics: Strategic partnership with Axial Biologics to enhance market penetration in pain management clinics, facilitating the deployment of CompuFlo.
Sales Pipeline Growth: Growing sales pipeline for CompuFlo with ongoing pilot programs in pain management clinics across the U.S.
Economic Conditions: General economic conditions could impact Milestone's ability to achieve expected revenue growth.
Regulatory Issues: Adverse patent rulings and FDA or legal developments may pose risks to the company's operations.
Competitive Pressures: The company faces competitive pressures that could affect its market position and revenue.
Market Requirements: Changes in customer and market requirements and standards could impact product adoption and sales.
Supply Chain Challenges: Logistic rate forward challenges were previously encountered, affecting international sales, although these have been resolved.
International Revenue Risks: The company recorded no revenue from China for the current period, indicating potential market risks.
Reimbursement Strategy: The success of the CompuFlo Epidural System is contingent on advancing reimbursement initiatives, which are critical for adoption.
Sales Pipeline Management: Balancing the growth of the sales pipeline while converting leads into sales presents an ongoing challenge.
Revenue Growth: Achieved a 22% increase in year-over-year revenue reaching $2.5 million, driven by strong growth in the dental division and a 57% increase in international dental sales.
E-commerce Transition: Shift to an e-commerce sales model has enhanced customer loyalty and satisfaction, resulting in improved gross margins of 73%.
CompuFlo Epidural System: Continued rollout with Medicare Part B payment rate assignment, expanding adoption among pain management clinics.
International Expansion: Secured regulatory approval in Brazil for CompuFlo, targeting a significant market opportunity with 2.8 million births annually.
Partnerships: Strategic partnership with Axial Biologics to enhance market penetration in pain management.
Sales Pipeline: Growing sales pipeline for CompuFlo with additional pilot programs planned across the U.S.
Future Revenue Expectations: Confident in the ability to drive further adoption of CompuFlo in both U.S. and international markets.
Market Opportunity: Medicare patients represent an estimated $250 million market opportunity for epidural procedures.
Financial Position: Maintained a strong balance sheet with approximately $4.8 million in cash and equivalents, sufficient to support growth without additional capital.
Operational Focus: Focus on advancing reimbursement initiatives and strengthening commercial infrastructure.
Sales Strategy: Plans to reduce revenue gap compared to the previous year through targeted marketing and customer reactivation efforts.
Shareholder Return Plan: Milestone Scientific has not announced any specific share buyback program or dividend program during this call. However, the management emphasized their commitment to driving shareholder value and maintaining a strong balance sheet with approximately $4.8 million in cash and cash equivalents as of September 30, 2024.
The earnings call summary indicates stagnant financial performance with no growth in gross profit and lack of detailed year-over-year comparisons for expenses. The Q&A section highlights uncertainties in commercialization and reimbursement strategies, as well as unclear management responses. Although there are plans to expand sales and marketing efforts, the lack of significant revenue growth or new partnerships, coupled with the absence of positive catalysts like guidance or shareholder returns, suggests a negative sentiment. The market is likely to react negatively, with a potential stock price decline of -2% to -8%.
The earnings call summary highlights a 22% YoY revenue increase, improved operational efficiency, and strong growth in the dental division. The Q&A section reveals a new partnership with Axial Biologics, which is a positive catalyst. Despite some risks and uncertainties, the company's strong balance sheet and commitment to shareholder value are favorable. Overall, the positive financial performance, strategic partnerships, and operational improvements suggest a positive stock price movement over the next two weeks.
The earnings call reveals declining revenue, increased losses, and unclear guidance, particularly around reimbursement and international sales strategies. Although e-commerce sales and gross margins improved, the overall financial performance is weak. The Q&A highlighted management's inability to provide specific future guidance, further adding to uncertainty. These factors suggest a negative sentiment, likely leading to a stock price decline in the short term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
